Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL448801 | 0.78 | ADORA2A (0.58) | AHCYADORA2AADORA3 | |
| SCHEMBL7573100 | 0.73 | ADORA2A (0.47) | ADORA2AADORA3 | |
| SCHEMBL29501905 | 0.73 | AHCY (0.73) | AHCYADORA2AADORA3 | |
| SCHEMBL447258 | 0.73 | AHCY (0.73) | AHCYADORA2AADORA3 | |
| SCHEMBL7206725 | 0.70 | PI4KA (0.59) | ADORA2AADORA3 | |
| SCHEMBL591104 | 0.69 | ADORA2A (1.00) | ADORA2AADORA3CDK1 | |
| SCHEMBL591839 | 0.69 | ADORA2A (1.00) | ADORA2AADORA3CDK1 | |
| SCHEMBL590747 | 0.69 | ADORA2A (1.00) | ADORA2AADORA3CDK1 | |
| Noraristeromycin SCHEMBL1231088 | 0.69 | AHCY (1.00) | AHCYADORA3 | |
| Noraristeromycin SCHEMBL17109603 | 0.69 | AHCY (1.00) | AHCYADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| US-9549943-B2 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | CAN-FITE BIOPHARMA LTD. (IL) | 2017-01-24 | — | — | US | disclosed |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | CAN-FITE BIOPHARMA LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-8557790-B2 | A3 adenoside receptor agonists for the reduction of intraocular pressure | CAN-FITE BIOPHARMA LTD. (IL) | 2013-10-15 | — | — | US | disclosed |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | CAN-FITE BIOPHARMA LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | CAN-FITE BIOPHARMA LTD. (IL) | 2008-12-04 | — | — | US | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
| US-5688774-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | AHCY 432/4885ADORA2A 2/4885ADORA3 1/4885 |
| US-20150216889-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | ADORA3, ADORA2A, ADORA2B | AHCY 618/4885ADORA2A 2/4885ADORA3 1/4885 |
| US-20080300213-A1 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment | ADORA3, ADORA2A, ADORA1 | AHCY 198/4885ADORA2A 2/4885ADORA3 1/4885 |
| US-20120065155-A1 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE | ADORA3, ADORA1, ADORA2A | AHCY 1800/4885ADORA2A 3/4885ADORA3 1/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | AHCY 714/4885ADORA2A 1/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.